Search Bar & Filters
Found 59 Actively Recruiting clinical trials
Actively Recruiting
Glycogen storage disorders GSD are inherited metabolic diseases affecting glycogen production or breakdown, mainly involving the liver and muscles. These disorders vary in severity from mild to fatal in infancy. This study focuses on hepatic GSD types 0a, I, III, IV, VI, IX, and XI in Indian children. It aims to establish a comprehensive Indian GSD registry to better understand the spectrum of genetic defects, natural progression, and how genetic variations relate to disease symptoms in this population. The study is a multicenter observational effort collecting both retrospective and ongoing prospective data from genetically confirmed pediatric hepatic GSD cases. It involves analyzing clinical presentations, outcomes, and genetic variations across multiple centers in India. Retrospective data collection and analysis are planned between May 2024 and April 2025, with continued data submission from new centers and periodic follow-up every 6 months to 1 year. The registry will help guide individualized treatment decisions, including medical therapy or liver transplantation. Participants are children diagnosed genetically with hepatic GSD. The research team reviews clinical data, genetic testing results, and long-term outcomes such as native liver survival and post-transplant complications. The study measures the association between specific gene variants and clinical disease expression over a 5-year period. This ongoing project aims to improve understanding of GSD in Indian children to support better diagnosis, management, and health policies.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of Datopotamab Deruxtecan Dato-DXd with or without durvalumab compared to chemotherapy chosen by doctors combined with pembrolizumab in people with PD-L1 positive locally recurrent inoperable or metastatic triple-negative breast cancer TNBC. This Phase III international study aims to see if Dato-DXd plus durvalumab can help patients live longer without their cancer worsening or improve overall survival, while also assessing impacts on quality of life. Participants are randomly assigned to one of three groups Dato-DXd with durvalumab, a chemotherapy option paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin combined with pembrolizumab, or Dato-DXd alone. All study drugs are given by intravenous infusion. The study will monitor patients for disease progression and response, with treatments and evaluations continuing for up to about 33 months. During the study, participants will undergo regular assessments including tumor measurements by imaging using RECIST 1.1 criteria, survival tracking, and quality of life evaluations focused on symptoms like breast and arm pain and physical functioning. Safety and drug effects will also be closely monitored throughout treatment and follow-up. The total study participation may last several years, with some outcomes measured up to 64 months from randomization.
Actively Recruiting
Researchers are evaluating elecoglipron, a drug administered orally once daily, for adults with type 2 diabetes mellitus T2DM who also have impaired kidney function and are receiving background treatment with dapagliflozin 10 mg, a sodium-glucose cotransporter 2 inhibitor SGLT2i. This phase III, randomized, double-blind study aims to assess the efficacy, safety, and tolerability of elecoglipron compared with placebo in this population, who are also on other glucose-lowering medications. Participants will be randomly assigned to receive either elecoglipron at one of two dose levels or a placebo, all given orally once daily alongside their background dapagliflozin treatment. The study uses a parallel-group design and will continue for 40 weeks, during which participants treatment adherence and response will be monitored closely. Throughout the study, participants will undergo regular assessments including measurements of hemoglobin A1c HbA1c from baseline to week 40, body weight, blood pressure, and fasting plasma glucose. Researchers will also track the time to initiation of any rescue medication and monitor for any hypoglycemic events. Safety and tolerability will be continuously evaluated during this period to understand the overall impact of elecoglipron compared to placebo.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults with Type 2 Diabetes Mellitus T2DM who are already being treated with insulin and other glucose-lowering medications. This Phase III study focuses on adults with T2DM who have had the condition for at least 90 days and meet certain health criteria. Participants will be randomly assigned to one of three groups elecoglipron at dose level 1, elecoglipron at dose level 2, or placebo. All treatments are taken orally once daily. The study treatment period lasts up to 40 weeks, during which participants continue their background insulin and glucose-lowering medications. During the study, participants will have regular assessments to monitor changes in blood sugar control, including Hemoglobin A1c HbA1c, body weight, blood pressure, and insulin dose. Researchers will also track safety, side effects, and tolerability. The main outcome is the change in HbA1c from baseline to Week 40. Overall, participation involves visits for monitoring and evaluations over approximately 40 weeks.
Actively Recruiting
Researchers are studying the effectiveness, safety, and tolerability of combining elecoglipron and dapagliflozin compared to using each drug alone in adults with type 2 diabetes mellitus T2DM who are not well controlled by lifestyle changes or other diabetes medications. This phase III trial aims to understand how well these treatments manage blood sugar levels in this population. Participants will be randomly assigned to one of five groups two different doses of elecoglipron combined with dapagliflozin, two doses of elecoglipron combined with a placebo matching dapagliflozin, or dapagliflozin alone with a placebo matching elecoglipron. All medications are taken orally once daily. The study uses a double-blind, parallel-group design to compare these treatments over 40 weeks. During the study, participants will have their blood sugar control measured primarily by changes in Hemoglobin A1c HbA1c from the start to week 40. Secondary measures include body weight changes, fasting plasma glucose, blood pressure, and time to starting rescue medication. Regular assessments will monitor safety and treatment effects throughout the trial period, which lasts about 40 weeks.
Actively Recruiting
Researchers are evaluating two commercially available trifocal toric intraocular lenses to compare their clinical outcomes and patient satisfaction in people undergoing cataract surgery. The main goal is to compare the distance-corrected intermediate visual acuity provided by these lenses. Additionally, the study aims to assess and compare the safety of the two trifocal toric intraocular lenses designed to correct astigmatism and improve vision at near, intermediate, and distance ranges. Participants will be randomly assigned to receive one of two types of trifocal toric intraocular lenses Optiflex TRIO or AcrySof IQ PanOptix. Both lenses are single-piece, posterior chamber foldable intraocular lenses with advanced aspheric optics and a trifocal design intended to reduce dependence on glasses. The Optiflex TRIO features a refractive-diffractive trifocal toric optic with a square edge design, while the AcrySof IQ PanOptix has a diffractive trifocal optic with a toric component. Each participant will receive one of these lenses based on randomization during cataract surgery. During the study, participants will be monitored for visual acuity outcomes, focusing on binocular distance-corrected intermediate vision at six months after lens implantation. Researchers will also track patient satisfaction and safety throughout the study period. The study includes preoperative assessments such as corneal topography or keratometry to measure astigmatism and will involve follow-ups to evaluate visual performance and any adverse effects. The total duration of participation varies but includes at least a six-month follow-up for outcome measurement.
Actively Recruiting
Researchers are evaluating how CDR132L, a potential new medicine, affects the structure and function of the heart in people living with heart failure. The study focuses on individuals with preserved ejection fraction and left ventricular hypertrophy. It is a phase 2, randomized, double-blind, placebo-controlled trial aimed at assessing the safety and efficacy of CDR132L on reversing cardiac remodeling. Participants will be randomly assigned to receive one of three different doses of CDR132L or a placebo. All treatments are given as intravenous infusions once every 4 weeks for 48 weeks. Throughout the study, participants will continue their individually tailored guideline-directed standard care therapy for heart failure. The trial duration is about 60 weeks. During the study, participants will undergo various assessments, including measuring changes in microRNA-132 levels as the primary outcome at 24 weeks. Secondary outcomes include changes in heart structure measured by cardiac magnetic resonance imaging and blood biomarkers, as well as monitoring adverse events up to 60 weeks. Participants will receive regular infusions and attend scheduled visits for monitoring and safety evaluations.
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Researchers are evaluating the anti-tumor effects of amivantamab combined with pembrolizumab and carboplatin compared to pembrolizumab, 5-fluorouracil, and platinum therapy in people with recurrent or metastatic head and neck squamous cell carcinoma HNSCC who have not received prior treatment for their advanced cancer. HNSCC affects tissues in the mouth and throat, and this study focuses on treatment-naive participants in this setting. Participants are assigned to one of two groups one receives pembrolizumab, amivantamab, and carboplatin, while the other receives pembrolizumab, 5-fluorouracil given as a 4-day infusion, and either carboplatin or cisplatin. The study compares these treatment combinations to assess their effects on the cancer over a period of up to about 3 years and 7 months. During the study, participants undergo evaluations including imaging scans to measure tumor response using RECIST criteria, blood tests to monitor drug levels and antibodies, and quality of life questionnaires focused on head and neck symptoms and overall health. Researchers track overall survival, tumor response rates, progression-free survival, duration of response, side effects, and symptom changes. The study involves regular visits for treatment and monitoring throughout the treatment and follow-up period.
1-10 of 59
1